M. Ishikawa

发表

Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.

Minoru Ishikawa, Yukihiro Itoh, Yuichi Hashimoto, 2010, Journal of the American Chemical Society.

Development of target protein-selective degradation inducer for protein knockdown.

Yukihiro Itoh, Y. Hashimoto, M. Naito, 2011, Bioorganic & medicinal chemistry.

Pseurotin A and its analogues as inhibitors of immunoglobulin E [correction of immunoglobuline E] production.

T. Murata, M. Ishikawa, T. Ninomiya, 2009, Bioorganic & medicinal chemistry letters.

Structural development of tetrachlorophthalimides as liver X receptor β (LXRβ)-selective agonists with improved aqueous solubility.

M. Makishima, Y. Hashimoto, M. Ishikawa, 2017, Bioorganic & medicinal chemistry letters.

1α-Hydroxy derivatives of 7-dehydrocholesterol are selective liver X receptor modulators

M. Makishima, Y. Hashimoto, S. Yamada, 2017, The Journal of Steroid Biochemistry and Molecular Biology.

Development of Tetrachlorophthalimides as Liver X Receptor β (LXRβ)‐Selective Agonists

M. Makishima, Y. Hashimoto, M. Ishikawa, 2016, ChemMedChem.

7-Dehydrocholesterol metabolites produced by sterol 27-hydroxylase (CYP27A1) modulate liver X receptor activity

M. Makishima, K. Yasuda, Y. Hashimoto, 2014, The Journal of Steroid Biochemistry and Molecular Biology.

Recent Progress in PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders.

M. Ishikawa, Shusuke Tomoshige, 2020, Angewandte Chemie.

PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders

M. Ishikawa, Shusuke Tomoshige, 2020 .

Structural basis for specific cleavage of Lys6-linked polyubiquitin chains by USP30

Y. Hashimoto, Y. Saeki, Keiji Tanaka, 2017, Nature Structural & Molecular Biology.

Discovery of Small Molecules that Induce the Degradation of Huntingtin.

Y. Hashimoto, M. Ishikawa, Kenji Ohgane, 2017, Angewandte Chemie.

Degradation of HaloTag-fused nuclear proteins using bestatin-HaloTag ligand hybrid molecules.

Y. Hashimoto, M. Naito, M. Ishikawa, 2015, Organic & biomolecular chemistry.

Application of protein knockdown strategy targeting β-sheet structure to multiple disease-associated polyglutamine proteins.

Y. Hashimoto, M. Ishikawa, H. Yamashita, 2019, Bioorganic & medicinal chemistry.

Structure Elucidation of Novel Metabolites of Gemfibrozil in Dog : Conjugation Reaction of Conjugated Metabolites

H. Yoshii, M. Ishikawa, H. Iwabuchi, 2004 .

Structure-activity relationships of rosiglitazone for peroxisome proliferator-activated receptor gamma transrepression.

M. Makishima, Y. Hashimoto, M. Ishikawa, 2017, Bioorganic & medicinal chemistry letters.

Efficient protein knockdown of HaloTag-fused proteins using hybrid molecules consisting of IAP antagonist and HaloTag ligand.

Y. Hashimoto, M. Ishikawa, Shusuke Tomoshige, 2016, Bioorganic & medicinal chemistry.

Degradation of huntingtin mediated by a hybrid molecule composed of IAP antagonist linked to phenyldiazenyl benzothiazole derivative.

Y. Hashimoto, M. Ishikawa, Kenji Ohgane, 2018, Bioorganic & medicinal chemistry letters.

G-Protein–Coupled Receptor Kinase 2 as a Potential Modulator of the Hallmarks of Cancer

Yukihiro Itoh, Y. Hashimoto, M. Naito, 2017, Molecular Pharmacology.

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part III: Synthesis of potent antagonists with αvβ3/αIIbβ3 dual activity and improved water solubility

M. Ishikawa, K. Ajito, Takashi Watanabe, 2006 .

Conversion of a PROTAC Mutant Huntingtin Degrader into Small-Molecule Hydrophobic Tags Focusing on Drug-like Properties.

H. Taguchi, S. Nakagawa, Y. Hashimoto, 2022, ACS medicinal chemistry letters.

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 2: Synthesis of potent αvβ3/αIIbβ3 dual antagonists

M. Ishikawa, K. Ajito, Mikio Yamamoto, 2006 .

Switching of Photocatalytic Tyrosine/Histidine Labeling and Application to Photocatalytic Proximity Labeling

M. Ishikawa, Shusuke Tomoshige, Shinichi Sato, 2022, International journal of molecular sciences.

Functionalization of Human Serum Albumin by Tyrosine Click

M. Ishikawa, Shusuke Tomoshige, Shinichi Sato, 2021, International journal of molecular sciences.

Biotransformation of Prasugrel, a Novel Thienopyridine Antiplatelet Agent, to the Pharmacologically Active Metabolite

Hiroyuki Kobayashi, N. Farid, A. Kurihara, 2010, Drug Metabolism and Disposition.

Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand.

M. Makishima, Y. Hashimoto, M. Ishikawa, 2014, Bioorganic & medicinal chemistry.

Proximity Histidine Labeling by Umpolung Strategy Using Singlet Oxygen.

H. Taguchi, Hiroyuki Nakamura, M. Ishikawa, 2021, Journal of the American Chemical Society.

Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.

M. Makishima, S. Okazaki, Y. Hashimoto, 2017, Bioorganic & medicinal chemistry letters.

A Scalable Synthesis of MN-447, an Antagonist for Integrins αvβ3 and αIIbβ3

Y. Kojima, M. Ishikawa, K. Ajito, 2008 .

Improvement in Aqueous Solubility of Retinoic Acid Receptor (RAR) Agonists by Bending the Molecular Structure.

M. Makishima, Y. Ichikawa, Y. Hashimoto, 2016, Chemistry, an Asian journal.

Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.

Minoru Ishikawa, Yuichi Hashimoto, Y. Hashimoto, 2011, Journal of medicinal chemistry.

Design, synthesis, and biological evaluation of novel transrepression-selective liver X receptor (LXR) ligands with 5,11-dihydro-5-methyl-11-methylene-6H-dibenz[b,e]azepin-6-one skeleton.

M. Makishima, Y. Hashimoto, H. Aoyama, 2012, Journal of medicinal chemistry.

Inhibition of restriction enzymes EcoRI, BamHI and HindIII by phenethylphenylphthalimides derived from thalidomide.

Y. Hashimoto, K. Sugita, M. Ishikawa, 2011, Chemical & pharmaceutical bulletin.

Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-related α-glucosidase inhibitors and liver X receptor antagonists.

Y. Hashimoto, K. Sugita, M. Ishikawa, 2011, Bioorganic & medicinal chemistry letters.

Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: relationship between absolute configuration and subtype selectivity.

Y. Hashimoto, K. Sugita, M. Ishikawa, 2011, Bioorganic & medicinal chemistry.

Further Application of the Multi-Template Approach for Creation of Biological Response Modifiers: Discovery of a New Class of Multifunctional Anti-Diabetic Agents

Y. Hashimoto, K. Sugita, M. Ishikawa, 2010 .

Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists.

Y. Hashimoto, K. Sugita, M. Ishikawa, 2009, Bioorganic & medicinal chemistry.

Design, synthesis and biological evaluation of nuclear receptor-degradation inducers.

Yukihiro Itoh, Y. Hashimoto, M. Naito, 2011, Bioorganic & medicinal chemistry.

Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton.

M. Makishima, Y. Hashimoto, H. Kagechika, 2018, ACS medicinal chemistry letters.

Novel selective anti-androgens with a diphenylpentane skeleton.

Y. Hashimoto, K. Sugita, M. Ishikawa, 2010, Bioorganic & medicinal chemistry letters.

Chemical Modification of Pseurotin A: One-pot Synthesis of Synerazol and Pseurotin E and Determination of Absolute Stereochemistry of Pseurotin E

M. Ishikawa, T. Ninomiya, 2008, The Journal of Antibiotics.

Disposition and Metabolism of the Oral Antidiabetic Drug Troglitazone in Monkeys

H. Haruyama, H. Ikenaga, M. Ishikawa, 2000 .

Development of tryptase inhibitors derived from thalidomide.

Y. Hashimoto, H. Aoyama, M. Ishikawa, 2010, Bioorganic & medicinal chemistry.

Improvement of water-solubility of biarylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) δ-selective partial agonists by disruption of molecular planarity/symmetry.

M. Makishima, Y. Hashimoto, H. Miyachi, 2010, Bioorganic & medicinal chemistry.

Specific degradation of CRABP‐II via cIAP1‐mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein

Yukihiro Itoh, Y. Hashimoto, M. Naito, 2011, FEBS letters.

Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs

M. Naito, M. Ishikawa, Shusuke Tomoshige, 2020, Pharmaceuticals.

Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist.

Yukihiro Itoh, Y. Hashimoto, M. Naito, 2012, Bioorganic & medicinal chemistry letters.

Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.

Y. Hashimoto, M. Ishikawa, Tomomi Noguchi-Yachide, 2013, Bioorganic & medicinal chemistry.

In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs).

M. Ishikawa, Shusuke Tomoshige, 2021, Bioorganic & medicinal chemistry.

Phenanthridin-6-one derivatives as the first class of non-steroidal pharmacological chaperones for Niemann-Pick disease type C1 protein.

Hiromitsu Fukuda, Minoru Ishikawa, Kenji Ohgane, 2017, Bioorganic & medicinal chemistry letters.

beta-Naphthoflavone analogs as potent and soluble aryl hydrocarbon receptor agonists: improvement of solubility by disruption of molecular planarity.

Y. Hashimoto, M. Ishikawa, Tomomi Noguchi-Yachide, 2010, Bioorganic & medicinal chemistry.

Image-based screen capturing misfolding status of Niemann-Pick type C1 identifies potential candidates for chaperone drugs

Mikiko Sodeoka, Yuichi Hashimoto, Kenji Ohgane, 2020, PloS one.

LXXLL peptide mimetics as inhibitors of the interaction of vitamin D receptor with coactivators.

M. Makishima, Y. Hashimoto, H. Miyachi, 2010, Bioorganic & medicinal chemistry letters.

Improvement in aqueous solubility of achiral symmetric cyclofenil by modification to a chiral asymmetric analog

M. Makishima, Y. Ichikawa, Y. Hashimoto, 2021, Scientific Reports.

Interaction of Modified Cyclodextrins with Cytochrome P-450

Minoru Ishikawa, T. Furuta, H. Yoshii, 2005, Bioscience, biotechnology, and biochemistry.

Photo-enhanced Aqueous Solubilization of an Azo-compound

Y. Norikane, M. Ishikawa, T. Ohzono, 2017, Scientific Reports.

Styrylphenylphthalimides as Novel Transrepression-Selective Liver X Receptor (LXR) Modulators.

M. Makishima, Y. Hashimoto, M. Ishikawa, 2015, ACS medicinal chemistry letters.

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part IV: Preliminary control of αvβ3 selectivity by meta-oriented substitution

M. Kitakaze, M. Ishikawa, K. Ajito, 2006 .

Structure-activity relationship of benzodiazepine derivatives as LXXLL peptide mimetics that inhibit the interaction of vitamin D receptor with coactivators.

Y. Hashimoto, M. Ishikawa, K. Dodo, 2013, Bioorganic & medicinal chemistry.

meta-Non-flat substituents: a novel molecular design to improve aqueous solubility in small molecule drug discovery.

M. Makishima, Y. Ichikawa, Y. Hashimoto, 2020, Organic & biomolecular chemistry.

Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.

Tomoatsu Hayashi, T. Akiyama, Y. Hashimoto, 2015, Bioorganic & medicinal chemistry.

Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERα-selective antagonist.

M. Makishima, Y. Hashimoto, K. Sugita, 2013, Bioorganic & medicinal chemistry letters.

Improving the Water-Solubility of Compounds by Molecular Modification to Disrupt Crystal Packing

Y. Hashimoto, M. Ishikawa, 2015 .

Design and synthesis of silicon-containing fatty acid amide derivatives as novel peroxisome proliferator-activated receptor (PPAR) agonists.

Y. Hashimoto, Yotaro Matsumoto, M. Ishikawa, 2015, Bioorganic & medicinal chemistry letters.

Discovery of N-(1-(3-(4-phenoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)acetamides as novel acetyl-CoA carboxylase 2 (ACC2) inhibitors with peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonistic activity.

M. Makishima, S. Okazaki, Y. Hashimoto, 2016, Bioorganic & medicinal chemistry.

Glycogen phosphorylase a inhibitors with a phenethylphenylphthalimide skeleton derived from thalidomide-related alpha-glucosidase inhibitors and liver X receptor antagonists.

Y. Hashimoto, K. Sugita, M. Ishikawa, 2009, Biological & pharmaceutical bulletin.

Specific fluorescence labeling of target proteins by using a ligand-4-azidophthalimide conjugate.

Y. Hashimoto, M. Sodeoka, M. Ishikawa, 2017, Chemical communications.

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 1: Design and synthesis of a lead compound exhibiting αvβ3/αIIbβ3 dual antagonistic activity

M. Ishikawa, M. Hachisu, K. Ajito, 2006 .

Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.

M. Makishima, S. Okazaki, Y. Hashimoto, 2016, Bioorganic & medicinal chemistry.